Article in ImmunoHorizons, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
Tibor KelerCelldex Therapeutics Inc., Hampton, NJ 08827.
Teresa P DiLorenzoDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461; teresa.dilorenzo@einstein.yu.edu.ORCID 0000-0003-4337-3598
Albert Einstein College of Medicine · USCelldex Therapeutics (United States) · US
Funding
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007288 · NIGMS · YESHIVA UNIVERSITY · PI AKABAS, MYLES H. · 1985 to 2022
$35.6M
Translational Research CoreP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY E. PESSIN · 2015 to 2026
$27.7M
Antigens Recognized by CD8+ T Cells in Type 1 DiabetesR01DK064315 · NIDDK · YESHIVA UNIVERSITY · PI DILORENZO, TERESA P · 2003 to 2015
$3.8M
Structural, functional, and mechanistic anlaysis of autoreactive CD8 T cellsR01AI123730 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ALMO, STEVEN C., DILORENZO, TERESA P · 2018 to 2022
$3.6M
T Cell Tolerance by DEC-205-mediated Islet Antigen Delivery to Dendritic CellsR01DK094327 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI DILORENZO, TERESA P · 2011 to 2015
$1.8M
An immunotherapeutic strategy for the induction and stabilization of remission in type 1 diabetesR01DK120420 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ALMO, STEVEN C., DILORENZO, TERESA P · 2018 to 2020
$1.5M
Use of beta cell epitopes in preventing type 1 diabetes in humanized miceF30DK103368 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI SCHLOSS, JENNIFER · 2014 to 2018
$198k
CD8 T Cell Epitope Mapping Using Mice Expressing HLA-A2 and a Human AutoantigenR03AI119225 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI DILORENZO, TERESA P · 2015 to 2016
Dendritic cells (DCs) are crucial for the production of adaptive immune responses to disease-causing microbes. However, in the steady state (i.e., in the absence of an infection or when Ags are experimentally delivered without a DC-activating adjuvant), DCs present Ags to T cells in a tolerogenic manner and are important for the establishment of peripheral tolerance. Delivery of islet Ags to DCs using Ag-linked Abs to the DC endocytic receptor CD205 has shown promise in the NOD mouse model of type 1 diabetes (T1D). It is important to note, however, that all myeloid DCs express CD205 in humans, whereas in mice, only one of the classical DC subsets does (classical DC1; CD8α
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Development and Characterization of a Preclinical Model for the Evaluation of CD205-Mediated Antigen Delivery Therapeutics in Type 1 Diabetes. · full record | Socratic